These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
294 related items for PubMed ID: 25482255
1. Does interferon beta therapy affect survival of multiple sclerosis patients? Kułakowska A, Drozdowski W. Neurol Neurochir Pol; 2014; 48(6):436-41. PubMed ID: 25482255 [Abstract] [Full Text] [Related]
2. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M. Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825 [Abstract] [Full Text] [Related]
3. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, Myhr KM, Søgaard LV, Olsen IC, Sandberg-Wollheim M. Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854 [Abstract] [Full Text] [Related]
6. The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study. Lacy M, Hauser M, Pliskin N, Assuras S, Valentine MO, Reder A. Mult Scler; 2013 Nov; 19(13):1765-72. PubMed ID: 23652214 [Abstract] [Full Text] [Related]
17. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Montalban X, Sastre-Garriga J, Tintoré M, Brieva L, Aymerich FX, Río J, Porcel J, Borràs C, Nos C, Rovira A. Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261 [Abstract] [Full Text] [Related]
18. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M, COGIMUS Study Group. Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846 [Abstract] [Full Text] [Related]
19. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D. Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959 [Abstract] [Full Text] [Related]